Pulmonary hypertension is a complication in at least 23% of patients with significant mitral regurgitation due to flail leaflet, and approximately doubles the risk of death and heart failure after diagnosis.
Mitral valve disease (symptomatic and asymptomatic) costs the U.S. at least $13.2 billion in direct healthcare expenditures each year.
[ Get More Details ]